Genesis hires Shifeng Pan as CSO, names Paul Friedman chair
Plus: Gen1E names François Nader chairman, and updates from Iambic and Boundless
Genesis Therapeutics Inc. named Shifeng Pan CSO and Alla Ivanova SVP of engineering. Pan joined Genesis in April from Odyssey Therapeutics Inc.; Ivanova joined in November from Google. The company added that Paul Friedman, former CEO of Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) and Incyte Corp. (NASDAQ:INCY), became chairman in April. Genesis is using AI for small molecule discovery.
Rare and inflammatory diseases company Gen1E Lifesciences Inc. named François Nader chair. Nader is a senior adviser at Blackstone Life Sciences and was chairman of the board of BenevolentAI S.A. (Euronext:BAI) until May...